This is an update to the previously published Saudi guidelines for the evaluation and medical/surgical management of patients diagnosed with urothelial cell carcinoma of the urinary bladder. It is categorized according to the stage of the disease using the tumor node metastasis staging system, 7 th edition. The guidelines are presented with their accompanying supporting evidence level, which is based on comprehensive literature review, several internationally recognized guidelines, and the collective expertise of the guidelines committee members (authors) who were selected by the Saudi Oncology Society and Saudi Urological Association. Considerations to the local availability of drugs, technology, and expertise have been regarded. These guidelines should serve as a roadmap for the urologists, oncologists, general physicians, support groups, and health-care policymakers in the management of patients diagnosed with urothelial cell carcinoma of the urinary bladder.
INTRODUCTION
According to the cancer incidence report in Saudi Arabia for the year 2013, there were 280 new cases of urinary bladder cancer, accounting for 4.3% and 0.8% of all newly diagnosed cases of cancer in men and women, respectively. Urinary bladder cancer is ranked the 8 th most common cancer in males and the 20 th most common in females. Of the 280 cases, 227 affected males (81%) and 53 affected females (19%). The overall age-standardized incidence rate was 3.8/100,000, in males and 1/100,000 in females. The median age at diagnosis was 63 years among males and 64 years among females. [1] 
STAGING
The American Joint Committee on Cancer tumor, nodes, metastases staging definitions for bladder cancer should be used [2] [ Tables 1 and 2 ].
TUMOR GRADING
The 2016 World Health Organization Classification of Tumors of the Urinary System [3] will be used as follows: [4] 
PATHOLOGY REPORTING
Surgical pathology reporting must include the following: 1. The histological tumor type 2. The presence or absence of lamina propria and muscularis propria 3. The depth of invasion (i.e., pathological T stage) referred to in Section 1 4. The presence or absence of carcinoma in situ (CIS) 5. The grade of tumor as referred to in Section 2 6. Any urothelial carcinoma variant. [5] 
EVALUATION OF THE BLADDER TUMOR
The initial evaluation should include history and physical examination, complete blood count, renal function, urine cytology, and bladder ultrasonography. Initial diagnostic cystoscopy should be done with transurethral bladder tumor resection (TURBT) to achieve complete resection if possible. [6] Imaging of the upper tract should be done by ultrasound, computed tomography (CT), or magnetic resonance imaging (MRI) urogram. If the cystoscopy findings confirm the invasive disease, do CT or MRI of abdomen and pelvis, as well as chest imaging. [7, 8] [9] [10] [11] iv. Provide further treatment according to risk stratification. 2. Risk stratification for nonmuscle invasive urothelial bladder carcinoma i. Risk depends on the following factors: T stage, the presence of CIS, grade, recurrence rate, number of tumors, and tumor size [12] [ Table 3 ] [13] ii. i. Intravesical bacillus Calmette-Guerin (BCG) or mitomycin induction (weekly for 6 weeks) [14] ii. Surveillance cystoscopy and cytology iii. Upper tract imaging every 2 years or as indicated. 5. Management of high-risk nonmuscle, invasive bladder cancer, including carcinoma in situ i. Intravesical BCG or mitomycin induction (weekly for 6 weeks) and maintenance therapy (3 weekly injections) at 3, 6, 12, 18, 24, 30, and 36 months from induction [15, 16] ii. Close surveillance cystoscopy, cytology, and upper tract imaging iii. Consider early cystectomy in selected patients. 6 . Recurrence of nonmuscle invasive disease i. TURBT ii. Adjuvant intravesical therapy if not given before or as a second induction [17] iii. If two inductions of adjuvant intravesical therapy were given before, then consider changing the intravesical therapy iv. Consider early cystectomy in recurrent CIS, T1, and high-grade disease with prior treatment with no >2 inductions of intravesical therapy. [18, 19] 7. Positive urine cytology without gross evidence of disease i. Multiple biopsies of the bladder and prostatic urethra [20] [21] [22] ii. Selective cytology of the upper tract iii. Upper tract imaging (CT, MRI, or retrograde pyelogram) iv. Ureteroscopy if suspicion of upper tract tumor.
MANAGEMENT OF MUSCLE-INVASIVE UROTHELIAL BLADDER CARCINOMA
Staging should include complete blood count; renal function; serum electrolytes; liver function test, including alkaline phosphatase; imaging of the chest, abdomen, and pelvis (CT or MRI); and a bone scan if elevated alkaline phosphatase or symptoms of bone pain are present. [23] 1. Clinical T2-T4a disease with negative lymph nodes i. Neoadjuvant cisplatin-based combination chemotherapy: [24] [25] [26] • Considered in clinical T2
• Strongly recommended in clinical T3. T IS  N0  M0  Stage I  T1  N0  M0  Stage II  T2a  N0  M0  T2b  N0  M0  Stage III  T3a  N0  M0  T3b  N0  M0  Stage IV  T4a  N0  M0  T4b  N0  M0  Any T N1-N3 M0 Any T Any N M1 is considered the standard treatment [27] iii. Bilateral pelvic lymphadenectomy should be performed and include, at a minimum, the common, internal and external iliac, and obturator nodes iv. Bladder preservation with trimodality combination of complete resection of the bladder tumor TURBT, followed by concurrent chemoradiation with early radical cystectomy in failure, are alternatives to upfront radical cystectomy [27] [28] [29] [30] [31] [32] in selected patients with solitary disease, no CIS, no hydronephrosis, normal renal function, and adequate bladder capacity [33] v. In patients undergoing bladder preservation, early evaluation by cystoscopy with or without biopsy is recommended after 40-45 Gy for the whole bladder and regional nodes. If there is residual/recurrent tumor, then consider cystectomy. If there is complete response, then complete radiotherapy to 60-65 Gy total dose in conventional fractionation; altered fractionation regimens, such as 50-52.5 Gy in 20 fractions, may also be considered [34] vi. For patients who are not candidates for radical treatment, consider TURBT and/or palliative radiotherapy vii. If no neoadjuvant chemotherapy is given, consider adjuvant cisplatin-based chemotherapy following pathological criteria (pT3-4, positive nodes). [35] 2. Clinical T4b or positive locoregional lymph node disease i. Cisplatin-based combination chemotherapy or chemoradiation ii. Reevaluate the response during the treatment with imaging and/or TURBT iii. If chemoradiation was used:
ii. R a d i c a l c y s t e c t o m y w i t h e x t e n d e d
• Observation for patients who achieved complete response.
• If partial response, consider cystectomy. iv. If cisplatin-based combination chemotherapy was used:
• In responding patients, consider cystectomy or chemoradiation
• In nonresponding patients, consider chemoradiation. 3. Metastatic disease i. Chemotherapy is the mainstay of treatment ii. Patients with normal renal function and fit for chemotherapy (performance status [PS] 0-2) are treated with combination cisplatin and gemcitabine for a maximum of six cycles [36] iii. Patients with decreased renal function and/or unfit (PS 3) are treated with combination of carboplatin and gemcitabine [37] or single-agent gemcitabine, carboplatin, or atezolizumab [38] iv. There is no standard, second-line therapy; patients who relapse or progress on the first-line may be given atezolizumab, [38] vinflunine, or taxanes as second-line chemotherapy v. Patients who present with local recurrence may benefit from palliative radiation therapy.
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